Zwitterionic Polymer Conjugates for Controlled Drug Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current polymer therapeutics face challenges in controlling the delivery and stability of biologically active compounds, particularly in achieving targeted delivery and minimizing immunogenicity and renal clearance, while maintaining solubility and stability in circulation.
Innovation Solution
The development of low polydispersity polymer conjugates using living radical polymerization processes, specifically atom transfer radical polymerization, with zwitterionic monomers and biologically active moieties, allows for controlled polymerization and conjugation of therapeutically active compounds, enhancing solubility and stability, and enabling targeted delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If conventional polymerisation processes are used to form polymer conjugates, then polymer therapeutics can be produced, but the polydispersity is high leading to poor control of delivery and stability
Solution Approach 1:
The patent applies living radical polymerisation techniques (ATRP, RAFT, NMP) that fundamentally change the polymerisation parameters and mechanism to achieve controlled molecular weight and narrow polydispersity (PDI < 1.5). This enables precise control over polymer conjugate properties including solubility, stability in circulation, renal clearance rate, and immunogenicity, directly resolving the contradiction between manufacturing precision and therapeutic reliability
2Stability of the object's composition
If zwitterionic groups are conjugated to therapeutically active compounds to improve solubility, then water solubility increases, but the synthetic process becomes complex involving multiple steps
Solution Approach 1:
The patent merges the polymerisation process with the conjugation process by incorporating zwitterionic monomers directly into the living polymerisation reaction. This single-step approach simultaneously creates the polymer backbone and attaches zwitterionic groups, eliminating the need for separate conjugation steps and significantly reducing synthetic complexity while maintaining high water solubility
Solution Approach 2:
The zwitterionic groups are incorporated into the monomer structure before polymerisation begins. This preliminary incorporation allows the functional groups to be uniformly distributed throughout the polymer chain from the start, avoiding the need for post-polymerisation modification and simplifying the overall synthetic route
3Duration of action of stationary object
If polymer molecular weight is increased to control renal clearance and improve circulation time, then therapeutic stability improves, but solubility may deteriorate
Solution Approach 1:
The patent changes the chemical composition parameters by incorporating zwitterionic monomers that provide permanent positive and negative charges. This compositional change enables the polymer to maintain high water solubility even at high molecular weights, resolving the contradiction between extended circulation time and solubility retention
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach results in polymers with controlled molecular weight and polydispersity, improving the solubility and stability of biologically active compounds, facilitating targeted delivery and minimizing renal clearance, thereby enhancing therapeutic efficacy and circulation time.
Implementation Method 1
The invention provides a polymerisation process in which ethylenically unsaturated monomers including a zwitterionic monomer are polymerised by a living radical polymerisation process in the presence of an initiator and a catalyst
Data Source
AI summary
The present invention relates to conjugates of biologically active compounds, preferably therapeutically active compounds, with polymeric moieties having low polydispersity, as well as controlled polymerisation processes for producing the conjugates. An initiation for a controlled radical polymerisation process comprises a biologically active, usually therapeutically active, moiety and the monomer includes zwitterionic monomer for instance 2-methacryloyloxyethyl -2′-trimethylammonium ethyl phosphate inner salt. The process allows close control of the molecular weight and polydispersity of the polymeric moiety and the possibility of optimizing the delivery characteristics of the active agent.